Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma

Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)

(2015) Liang-Chuan S. Wang et al.   NEOPLASIA

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

(2013) S M Tijono et al.   BRITISH JOURNAL OF CANCER

Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid

(2013) J. Conlon et al.   JOURNAL OF IMMUNOLOGY

Vascular priming enhances chemotherapeutic efficacy against head and neck cancer

(2013) Margaret Folaron et al.   ORAL ONCOLOGY

5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential

(2012) Daniel Prantner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Examination of blood–brain barrier (BBB) integrity in a mouse brain tumor model

(2012) Ngoc H. On et al.   JOURNAL OF NEURO-ONCOLOGY

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Treatment-Related Mortality With Bevacizumab in Cancer Patients

(2011) Vishal Ranpura et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

(2011) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ASSAY FOR THE DETERMINATION OF A FLUORINATED ANALOGUE OF THALIDOMIDE, N-(2,6-DIOXOPIPERIDIN-3-YL)-3,4,5,6-TETRAFLUOROPHTHALAMIC ACID, AND LENALIDOMIDE

(2011) Kaveshree Pather et al.   JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Advances in the Treatment of Malignant Gliomas

(2010) Mustafa Khasraw et al.   Current Oncology Reports

MRI-Based Characterization of Vascular Disruption by 5,6-Dimethylxanthenone-Acetic Acid in Gliomas

(2009) Mukund Seshadri et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

(2008) Gondi Kumar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

(2008) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY